Assessment of &agr;-Synuclein Pathology: A Study of the BrainNet Europe Consortium

To determine the reliability of assessment of &agr;-synuclein-immunoreactive (&agr;S-IR) structures by neuropathologists, 28 evaluators from 17 centers of BrainNet Europe examined current methods and reproducibility of &agr;S-IR evaluation using a tissue microarray (TMA) technique. Tissue microarray blocks were constructed of samples from the participating centers that contained &agr;S-IR structures. Slides from these blocks were stained in each center and assessed for neuronal perikaryal inclusions, neurites, and glial cytoplasmic inclusions. The study was performed in 2 phases. First, the TMA slides were stained with the antibody of the center's choice. In this phase, 59% of the sections were of good or acceptable quality, and 4 of 9 antibodies used performed consistently. Differences in interpretation and categorization of &agr;S-IR structures, however, led to differing results between the laboratories. Prior to the second phase, the neuropathologists participated in a training session on the evaluation of &agr;S-IR structures. Based on the results of the first phase, selected antibodies using designated antigen retrieval methods were then applied to TMA slides in the second phase. When the designated methods of both staining and evaluation were applied, all 26 subsequently stained TMA sections evaluated were of good/acceptable quality, and a high level of concordance in the assessment of the presence or absence of specific &agr;S-IR structures was achieved. A semiquantitative assessment of &agr;S-IR neuronal perikaryal inclusions yielded agreements ranging from 49% to 82%, with best concordance in cortical core samples. These results suggest that rigorous methodology and dichotomized assessment (i.e. determining the presence or absence of &agr;S-IR) should be applied, and that semiquantitative assessment can be recommended only for the cortical samples. Moreover, the study demonstrates that there are limitations in the scoring of &agr;S-IR structures.

[1]  I. Alafuzoff,et al.  Human Postmortem Brain Tissue and 2-mm Tissue Microarrays , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[2]  I. Ferrer,et al.  Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium , 2006, Journal of neuropathology and experimental neurology.

[3]  M. Graeber,et al.  Comparative study of commercially available anti‐α‐synuclein antibodies , 2006, Neuropathology and applied neurobiology.

[4]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[5]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[6]  J. Troncoso,et al.  Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases , 2005, Neurobiology of Aging.

[7]  H. Braak,et al.  Staging of Sporadic Parkinson Disease-Related α-Synuclein Pathology: Inter- and Intra-Rater Reliability , 2005, Journal of neuropathology and experimental neurology.

[8]  E. Kuusisto,et al.  Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α‐Synuclein, Ubiquitin, and p62 , 2003, Journal of neuropathology and experimental neurology.

[9]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[10]  Thomas Rüdiger,et al.  Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.

[11]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[12]  E. Masliah,et al.  Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[13]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[14]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[15]  B. Crain,et al.  Interlaboratory Comparison of Neuropathology Assessments in Alzheimer's Disease: A Study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Journal of neuropathology and experimental neurology.

[16]  H. Battifora The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. , 1986, Laboratory investigation; a journal of technical methods and pathology.